FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair

FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair

Abstract Inducing homologous-recombination (HR) deficiency is an effective strategy to broaden the indications of PARP inhibitors in the treatment of triple-negative breast cancer (TNBC). Herein, we find that repression of the oncogenic transcription factor FOXM1 using FOXM1 shRNA or FOXM1 inhibitor...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों:	Shu-Ping Wang, Shi-Qi Wu, Shi-Hui Huang, Yi-Xuan Tang, Liu-Qiong Meng, Feng Liu, Qi-Hua Zhu, Yun-Gen Xu
स्वरूप:	लेख
भाषा:	English
प्रकाशित:	Nature Publishing Group 2021-12-01
श्रृंखला:	Cell Death and Disease
ऑनलाइन पहुंच:	https://doi.org/10.1038/s41419-021-04434-9

समान संसाधन

BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
द्वारा: Yu Li, और अन्य
प्रकाशित: (2021-02-01)

Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib
द्वारा: Khwanjira Hongthong, और अन्य
प्रकाशित: (2021-08-01)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
द्वारा: Ambikai Gajan, और अन्य
प्रकाशित: (2021-07-01)

Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells
द्वारा: Miki Kawanishi, और अन्य
प्रकाशित: (2022-03-01)

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
द्वारा: S. Mazzucchelli, और अन्य
प्रकाशित: (2017-08-01)

DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors
द्वारा: Yaqin Shi, और अन्य
प्रकाशित: (2019-06-01)

Case report: Emerging BRCA mutation confers benefit from olaparib after chemotherapy intolerance in advanced triple‐negative breast cancer
द्वारा: Xia‐Bo Shen, और अन्य
प्रकाशित: (2024-04-01)

BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib
द्वारा: Carolina Velazquez, और अन्य
प्रकाशित: (2023-03-01)

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report
द्वारा: Auro del Giglio, और अन्य
प्रकाशित: (2023-09-01)

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
द्वारा: Abraham, JE, और अन्य
प्रकाशित: (2024)

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells
द्वारा: Chinnadurai Mani, और अन्य
प्रकाशित: (2019-09-01)

Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cells
द्वारा: Wanhong He, और अन्य
प्रकाशित: (2024-12-01)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells
द्वारा: Brian T. Burgess, और अन्य
प्रकाशित: (2020-02-01)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
द्वारा: Hong Yang, और अन्य
प्रकाशित: (2020-11-01)

The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib
द्वारा: Tianran Chen, और अन्य
प्रकाशित: (2017-10-01)

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study
द्वारा: Alfonso Cortés, और अन्य
प्रकाशित: (2024-12-01)

Activated NAD+ biosynthesis pathway induces olaparib resistance in BRCA1 knockout pancreatic cancer cells
द्वारा: Yuka Sasaki, और अन्य
प्रकाशित: (2024-01-01)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
द्वारा: Shinya Yamamoto, और अन्य
प्रकाशित: (2023-06-01)

Concurrent Olaparib and Radiation Therapy for BRCA2-Mutated Breast Cancer
द्वारा: Danny Lavigne, MD, और अन्य
प्रकाशित: (2024-07-01)

Olaparib-Resistant <i>BRCA2</i><sup>MUT</sup> Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival
द्वारा: Łukasz Biegała, और अन्य
प्रकाशित: (2023-03-01)

OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer
द्वारा: Nicum, S, और अन्य
प्रकाशित: (2017)

A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer
द्वारा: Fang W, और अन्य
प्रकाशित: (2023-10-01)

BRCA2‐positive lung adenocarcinoma treated with olaparib: A case report
द्वारा: Takumi Motohashi, और अन्य
प्रकाशित: (2024-03-01)

Adjuvant olaparib in germline BRCA-mutated breast cancer – Standard of care for all?
द्वारा: Shuvadeep Ganguly, और अन्य
प्रकाशित: (2021-01-01)

BRCA2 mutations and triple-negative breast cancer.
द्वारा: Peter Meyer, और अन्य
प्रकाशित: (2012-01-01)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
द्वारा: Na Li, और अन्य
प्रकाशित: (2021-04-01)

Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib
द्वारा: Roberts, Cai M., और अन्य
प्रकाशित: (2025)

Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant
द्वारा: Soon, Jonathan Jian Hao, और अन्य
प्रकाशित: (2023)

Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib
द्वारा: Riko Ikeda, और अन्य
प्रकाशित: (2024-03-01)

Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin
द्वारा: Yoshiyuki Miyazawa, और अन्य
प्रकाशित: (2023-01-01)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
द्वारा: Lorusso D, और अन्य
प्रकाशित: (2018-05-01)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
द्वारा: Maksimenko Jelena, और अन्य
प्रकाशित: (2012-12-01)

A case of double‐negative prostate cancer with BRCA2 mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab
द्वारा: Hiroki Tanaka, और अन्य
प्रकाशित: (2024-09-01)

Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer
द्वारा: Stefania Morganti, और अन्य
प्रकाशित: (2024-04-01)

CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines
द्वारा: Andréa Witz, और अन्य
प्रकाशित: (2023-10-01)

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
द्वारा: Juan Miguel Baquero, और अन्य
प्रकाशित: (2022-05-01)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
द्वारा: Dominik Glodzik, और अन्य
प्रकाशित: (2020-07-01)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
द्वारा: Elisena Franzese, और अन्य
प्रकाशित: (2019-11-01)

Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice
द्वारा: Li-Mei Chen, और अन्य
प्रकाशित: (2022-09-01)

Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib
द्वारा: Vlad-Adrian Afrăsânie, और अन्य
प्रकाशित: (2024-08-01)